News
All News
Publications
All PublicationsPharmTechPharmTech Europe
Multimedia
All VideosAsk the ExpertBehind The HeadlinesDrug Digest VideosDrug Solutions Podcast
Conferences
Conference CoverageConference Listing
More
Webcasts
Resources
ICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPartnersPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksState of the ScienceWhitepapers

Subscribe

  • News
  • Publications
  • Multimedia
  • Conferences
  • Webcasts
  • Resources
  • Subscribe
  • Analytics
    • Bio/Pharmaceutical Analysis Techniques
    • Laboratory Equipment and Instruments
  • Data and Artificial Intelligence
  • Dosage Forms
    • Solid/Semi-Solid Dosage
    • Specialty Dosage Drugs
    • Parenterals and Injectables
    • Inhalation Drugs
  • Drug Development
    • Intellectual Property and Patents
    • Process and Scaling
    • APIs and Excipients
    • Ingredients
    • Formulation and Drug Delivery
  • Manufacturing
    • Aseptic/Sterile Processing
    • Equipment
    • Process and Automation
    • Manufacturing, Parenterals and Injectables
    • Manufacturing, Biosimilars and Biobetters
    • Manufacturing, Inhalation Drugs
    • Manufacturing, Solid and Semi-Solid Dosage Drugs
    • Manufacturing, Cell Therapies
    • Manufacturing, Biologic Drugs
    • Supply Chain
    • Manufacturing, Gene Therapies
    • Packaging and Distribution
  • Outsourcing
    • Contract Research Services
    • Contract Analytical Services
    • Contract Development Services
    • Regulatory Consulting
    • Logistics and Distribution
    • Contract Manufacturing Services
  • Quality Systems
    • Ask the Expert
    • Quality Assurance/Quality Control
    • Regulatory Oversight and Compliance
Spotlight -
Analytics|
Dosage Forms|
Drug Development|
Manufacturing|
Outsourcing|
Quality Systems
Advertisement

Tawnya Flick

Advertisement

Tawnya Flick is principal scientist at Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320.

Articles by Tawnya Flick

Quantitation of Mutagenic Impurities in APIs Using a Platform Chip-Based CE–MS Method

ByJ. Scott Mellors,Helen Yan,Burton Lee,Jiemin Bao,Tawnya Flick,Laura E. Blue
August 2nd 2019

The ZipChip CE-ESI interface was evaluated for suitability as a platform approach for quantitation of MIs in API.

Advertisement

Latest Updated Articles

  • Quantitation of Mutagenic Impurities in APIs Using a Platform Chip-Based CE–MS Method
    Quantitation of Mutagenic Impurities in APIs Using a Platform Chip-Based CE–MS Method

    Published: August 2nd 2019 | Updated:



Advertisement
Advertisement

Trending on Pharmaceutical Technology

1

Batch Certification for New Manufacturing Technologies: The Qualified Person Role in a Digital Environment

2

Why Pharma’s AI Agents Need Smaller, Domain-Specific Models First

3

Drug Digest: Closing the Gap in Modern Process Control and Automation for QC/QA

4

How a “Plan, Prevent, Prove” Approach Helps Avoid Facility and Equipment Problems

5

BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation

  • About Us
  • Advertise
  • Contact Us
  • Editorial Info
  • Editorial Advisory Board
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us